ID   KPCI_HUMAN              Reviewed;         596 AA.
AC   P41743; D3DNQ4; Q8WW06;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   16-JUN-2009, sequence version 2.
DT   12-OCT-2022, entry version 232.
DE   RecName: Full=Protein kinase C iota type;
DE            EC=2.7.11.13;
DE   AltName: Full=Atypical protein kinase C-lambda/iota;
DE            Short=PRKC-lambda/iota;
DE            Short=aPKC-lambda/iota;
DE   AltName: Full=nPKC-iota;
GN   Name=PRKCI; Synonyms=DXS1179E;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=8226978; DOI=10.1016/s0021-9258(20)80525-0;
RA   Selbie L.A., Schmitz-Peiffer C., Sheng Y., Biden T.J.;
RT   "Molecular cloning and characterization of PKC iota, an atypical isoform of
RT   protein kinase C derived from insulin-secreting cells.";
RL   J. Biol. Chem. 268:24296-24302(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Teratocarcinoma;
RX   PubMed=7607695; DOI=10.1016/0888-7543(95)80190-w;
RA   Mazzarella R., Ciccodicola A., Esposito T., Arcucci A., Migliaccio C.,
RA   Jones C., Schlessinger D., D'Urso M., D'Esposito M.;
RT   "Human protein kinase C iota gene (PRKCI) is closely linked to the BTK gene
RT   in Xq21.3.";
RL   Genomics 26:629-631(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH SMG1, AND ACTIVITY REGULATION.
RX   PubMed=8524286; DOI=10.1128/mcb.16.1.105;
RA   Diaz-Meco M.T., Municio M.M., Sanchez P., Lozano J., Moscat J.;
RT   "Lambda-interacting protein, a novel protein that specifically interacts
RT   with the zinc finger domain of the atypical protein kinase C isotype
RT   lambda/iota and stimulates its kinase activity in vitro and in vivo.";
RL   Mol. Cell. Biol. 16:105-114(1996).
RN   [6]
RP   FUNCTION IN CELL SURVIVAL.
RX   PubMed=9346882; DOI=10.1074/jbc.272.44.27521;
RA   Murray N.R., Fields A.P.;
RT   "Atypical protein kinase C iota protects human leukemia cells against drug-
RT   induced apoptosis.";
RL   J. Biol. Chem. 272:27521-27524(1997).
RN   [7]
RP   INTERACTION WITH SQSTM1, AND SUBCELLULAR LOCATION.
RX   PubMed=9566925; DOI=10.1128/mcb.18.5.3069;
RA   Sanchez P., De Carcer G., Sandoval I.V., Moscat J., Diaz-Meco M.T.;
RT   "Localization of atypical protein kinase C isoforms into lysosome-targeted
RT   endosomes through interaction with p62.";
RL   Mol. Cell. Biol. 18:3069-3080(1998).
RN   [8]
RP   FUNCTION IN CELL SURVIVAL.
RX   PubMed=10467349; DOI=10.1038/sj.cdd.4400548;
RA   Wooten M.W., Seibenhener M.L., Zhou G., Vandenplas M.L., Tan T.H.;
RT   "Overexpression of atypical PKC in PC12 cells enhances NGF-responsiveness
RT   and survival through an NF-kappaB dependent pathway.";
RL   Cell Death Differ. 6:753-764(1999).
RN   [9]
RP   INTERACTION WITH SQSTM1 AND IKBKB, AND FUNCTION.
RX   PubMed=10356400; DOI=10.1093/emboj/18.11.3044;
RA   Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.;
RT   "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB
RT   activation.";
RL   EMBO J. 18:3044-3053(1999).
RN   [10]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF LYS-274.
RX   PubMed=10906326; DOI=10.1074/jbc.m002742200;
RA   Spitaler M., Villunger A., Grunicke H., Uberall F.;
RT   "Unique structural and functional properties of the ATP-binding domain of
RT   atypical protein kinase C-iota.";
RL   J. Biol. Chem. 275:33289-33296(2000).
RN   [11]
RP   FUNCTION IN CELL SURVIVAL.
RX   PubMed=11042363; DOI=10.1016/s0169-328x(00)00187-x;
RA   Xie J., Guo Q., Zhu H., Wooten M.W., Mattson M.P.;
RT   "Protein kinase C iota protects neural cells against apoptosis induced by
RT   amyloid beta-peptide.";
RL   Brain Res. Mol. Brain Res. 82:107-113(2000).
RN   [12]
RP   INTERACTION WITH PARD6A; PARD6B AND PARD6G, AND SUBUNIT OF A COMPLEX
RP   CONTAINING PARD6B AND CDC42/RAC1.
RX   PubMed=11260256; DOI=10.1046/j.1365-2443.2001.00404.x;
RA   Noda Y., Takeya R., Ohno S., Naito S., Ito T., Sumimoto H.;
RT   "Human homologues of the Caenorhabditis elegans cell polarity protein PAR6
RT   as an adaptor that links the small GTPases Rac and Cdc42 to atypical
RT   protein kinase C.";
RL   Genes Cells 6:107-119(2001).
RN   [13]
RP   INTERACTION WITH PARD3 AND PARD6B IN THE TERNARY AKPC/PAR3/PAR6 COMPLEX.
RX   PubMed=11257119; DOI=10.1083/jcb.152.6.1183;
RA   Suzuki A., Yamanaka T., Hirose T., Manabe N., Mizuno K., Shimizu M.,
RA   Akimoto K., Izumi Y., Ohnishi T., Ohno S.;
RT   "Atypical protein kinase C is involved in the evolutionarily conserved par
RT   protein complex and plays a critical role in establishing epithelia-
RT   specific junctional structures.";
RL   J. Cell Biol. 152:1183-1196(2001).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH GAPDH.
RX   PubMed=11724794; DOI=10.1074/jbc.m109744200;
RA   Tisdale E.J.;
RT   "Glyceraldehyde-3-phosphate dehydrogenase is phosphorylated by protein
RT   kinase Ciota /lambda and plays a role in microtubule dynamics in the early
RT   secretory pathway.";
RL   J. Biol. Chem. 277:3334-3341(2002).
RN   [15]
RP   PHOSPHORYLATION AT TYR-265; TYR-280 AND TYR-334, AND MUTAGENESIS OF
RP   TYR-265; TYR-280 AND TYR-334.
RX   PubMed=11713277; DOI=10.1128/mcb.21.24.8414-8427.2001;
RA   Wooten M.W., Vandenplas M.L., Seibenhener M.L., Geetha T., Diaz-Meco M.T.;
RT   "Nerve growth factor stimulates multisite tyrosine phosphorylation and
RT   activation of the atypical protein kinase C's via a src kinase pathway.";
RL   Mol. Cell. Biol. 21:8414-8427(2001).
RN   [16]
RP   INTERACTION WITH KPNB1, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-265,
RP   AND MUTAGENESIS OF TYR-265.
RX   PubMed=11891849; DOI=10.1002/jcb.10101.abs;
RA   White W.O., Seibenhener M.L., Wooten M.W.;
RT   "Phosphorylation of tyrosine 256 facilitates nuclear import of atypical
RT   protein kinase C.";
RL   J. Cell. Biochem. 85:42-53(2002).
RN   [17]
RP   INTERACTION WITH ADAP1.
RX   PubMed=12893243; DOI=10.1016/s0006-291x(03)01187-2;
RA   Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D.,
RA   Wakefield R.I.D., Johannes F.-J., Aitken A.;
RT   "Centaurin-alpha(1) associates with and is phosphorylated by isoforms of
RT   protein kinase C.";
RL   Biochem. Biophys. Res. Commun. 307:459-465(2003).
RN   [18]
RP   INTERACTION WITH PARD6B/PAR-6 AND LLGL1.
RX   PubMed=12725730; DOI=10.1016/s0960-9822(03)00244-6;
RA   Yamanaka T., Horikoshi Y., Sugiyama Y., Ishiyama C., Suzuki A., Hirose T.,
RA   Iwamatsu A., Shinohara A., Ohno S.;
RT   "Mammalian Lgl forms a protein complex with PAR-6 and aPKC independently of
RT   PAR-3 to regulate epithelial cell polarity.";
RL   Curr. Biol. 13:734-743(2003).
RN   [19]
RP   FUNCTION.
RX   PubMed=12871960; DOI=10.1074/jbc.m305381200;
RA   Tisdale E.J., Wang J., Silver R.B., Artalejo C.R.;
RT   "Atypical protein kinase C plays a critical role in protein transport from
RT   pre-Golgi intermediates.";
RL   J. Biol. Chem. 278:38015-38021(2003).
RN   [20]
RP   INTERACTION WITH RAB2A.
RX   PubMed=14570876; DOI=10.1074/jbc.m309343200;
RA   Tisdale E.J.;
RT   "Rab2 interacts directly with atypical protein kinase C (aPKC) iota/lambda
RT   and inhibits aPKCiota/lambda-dependent glyceraldehyde-3-phosphate
RT   dehydrogenase phosphorylation.";
RL   J. Biol. Chem. 278:52524-52530(2003).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF IRAK1.
RX   PubMed=14684752; DOI=10.1074/jbc.c300431200;
RA   Mamidipudi V., Lin C., Seibenhener M.L., Wooten M.W.;
RT   "Regulation of interleukin receptor-associated kinase (IRAK)
RT   phosphorylation and signaling by iota protein kinase C.";
RL   J. Biol. Chem. 279:4161-4165(2004).
RN   [22]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15994303; DOI=10.1074/jbc.m505402200;
RA   Regala R.P., Weems C., Jamieson L., Copland J.A., Thompson E.A.,
RA   Fields A.P.;
RT   "Atypical protein kinase Ciota plays a critical role in human lung cancer
RT   cell growth and tumorigenicity.";
RL   J. Biol. Chem. 280:31109-31115(2005).
RN   [23]
RP   INTERACTION WITH CDK7, AND SUBCELLULAR LOCATION.
RX   PubMed=15695176; DOI=10.1016/j.tice.2004.10.004;
RA   Bicaku E., Patel R., Acevedo-Duncan M.;
RT   "Cyclin-dependent kinase activating kinase/Cdk7 co-localizes with PKC-iota
RT   in human glioma cells.";
RL   Tissue Cell 37:53-58(2005).
RN   [24]
RP   INTERACTION WITH WDFY2.
RX   PubMed=16792529; DOI=10.1042/bj20060511;
RA   Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M., Bosse M.,
RA   Zimmermann S., Frey A.D., Caelers A., Bachmann A.S., Moelling K.;
RT   "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda.";
RL   Biochem. J. 399:9-20(2006).
RN   [25]
RP   INTERACTION WITH RAB2A AND GADPH, PHOSPHORYLATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=16452474; DOI=10.1074/jbc.m513031200;
RA   Tisdale E.J., Artalejo C.R.;
RT   "Src-dependent protein kinase C iota/lambda (aPKCiota/lambda) tyrosine
RT   phosphorylation is required for aPKCiota/lambda association with Rab2 and
RT   glyceraldehyde-3-phosphate dehydrogenase on pre-Golgi intermediates.";
RL   J. Biol. Chem. 281:8436-8442(2006).
RN   [26]
RP   INTERACTION WITH VAMP2.
RX   PubMed=17313651; DOI=10.1111/j.1742-4658.2007.05702.x;
RA   Fritzius T., Frey A.D., Schweneker M., Mayer D., Moelling K.;
RT   "WD-repeat-propeller-FYVE protein, ProF, binds VAMP2 and protein kinase
RT   Czeta.";
RL   FEBS J. 274:1552-1566(2007).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF EZR.
RX   PubMed=18270268; DOI=10.1242/jcs.016246;
RA   Wald F.A., Oriolo A.S., Mashukova A., Fregien N.L., Langshaw A.H.,
RA   Salas P.J.;
RT   "Atypical protein kinase C (iota) activates ezrin in the apical domain of
RT   intestinal epithelial cells.";
RL   J. Cell Sci. 121:644-654(2008).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [31]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=19327373; DOI=10.1016/j.mvr.2009.01.014;
RA   Staiger K., Schatz U., Staiger H., Weyrich P., Haas C., Guirguis A.,
RA   Machicao F., Haering H.U., Kellerer M.;
RT   "Protein kinase C iota mediates lipid-induced apoptosis of human coronary
RT   artery endothelial cells.";
RL   Microvasc. Res. 78:40-44(2009).
RN   [32]
RP   INTERACTION WITH ECT2 AND PARD6A, AND MUTAGENESIS OF ASP-72.
RX   PubMed=19617897; DOI=10.1038/onc.2009.217;
RA   Justilien V., Fields A.P.;
RT   "Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular
RT   transformation.";
RL   Oncogene 28:3597-3607(2009).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [34]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT PRO-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT THR-3; SER-7; SER-8 AND THR-9, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [36]
RP   FUNCTION IN PHOSPHORYLATION OF BAD.
RX   PubMed=21419810; DOI=10.1016/j.bbamcr.2011.03.007;
RA   Desai S., Pillai P., Win-Piazza H., Acevedo-Duncan M.;
RT   "PKC-? promotes glioblastoma cell survival by phosphorylating and
RT   inhibiting BAD through a phosphatidylinositol 3-kinase pathway.";
RL   Biochim. Biophys. Acta 1813:1190-1197(2011).
RN   [37]
RP   FUNCTION IN PHOSPHORYLATION OF ECT2.
RX   PubMed=21189248; DOI=10.1074/jbc.m110.196113;
RA   Justilien V., Jameison L., Der C.J., Rossman K.L., Fields A.P.;
RT   "Oncogenic activity of Ect2 is regulated through protein kinase C iota-
RT   mediated phosphorylation.";
RL   J. Biol. Chem. 286:8149-8157(2011).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-564, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-564, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [41]
RP   STRUCTURE BY NMR OF 25-108, INTERACTION WITH SQSTM1 AND MAP2K5, AND
RP   MUTAGENESIS OF LYS-29 AND ASP-72.
RX   PubMed=15143057; DOI=10.1074/jbc.m403092200;
RA   Hirano Y., Yoshinaga S., Ogura K., Yokochi M., Noda Y., Sumimoto H.,
RA   Inagaki F.;
RT   "Solution structure of atypical protein kinase C PB1 domain and its mode of
RT   interaction with ZIP/p62 and MEK5.";
RL   J. Biol. Chem. 279:31883-31890(2004).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 25-108 IN COMPLEX WITH PARD6A, AND
RP   MUTAGENESIS OF ASP-72; GLU-85 AND ARG-91.
RX   PubMed=15590654; DOI=10.1074/jbc.m409823200;
RA   Hirano Y., Yoshinaga S., Takeya R., Suzuki N.N., Horiuchi M., Kohjima M.,
RA   Sumimoto H., Inagaki F.;
RT   "Structure of a cell polarity regulator, a complex between atypical PKC and
RT   Par6 PB1 domains.";
RL   J. Biol. Chem. 280:9653-9661(2005).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 233-596, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND PHOSPHORYLATION AT THR-412 AND THR-564.
RX   PubMed=16125198; DOI=10.1016/j.jmb.2005.07.060;
RA   Messerschmidt A., Macieira S., Velarde M., Baedeker M., Benda C.,
RA   Jestel A., Brandstetter H., Neuefeind T., Blaesse M.;
RT   "Crystal structure of the catalytic domain of human atypical protein kinase
RT   C-iota reveals interaction mode of phosphorylation site in turn motif.";
RL   J. Mol. Biol. 352:918-931(2005).
RN   [44]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-118 AND CYS-130.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium- and diacylglycerol-independent serine/ threonine-
CC       protein kinase that plays a general protective role against apoptotic
CC       stimuli, is involved in NF-kappa-B activation, cell survival,
CC       differentiation and polarity, and contributes to the regulation of
CC       microtubule dynamics in the early secretory pathway. Is necessary for
CC       BCR-ABL oncogene-mediated resistance to apoptotic drug in leukemia
CC       cells, protecting leukemia cells against drug-induced apoptosis. In
CC       cultured neurons, prevents amyloid beta protein-induced apoptosis by
CC       interrupting cell death process at a very early step. In glioblastoma
CC       cells, may function downstream of phosphatidylinositol 3-kinase
CC       (PI(3)K) and PDPK1 in the promotion of cell survival by phosphorylating
CC       and inhibiting the pro-apoptotic factor BAD. Can form a protein complex
CC       in non-small cell lung cancer (NSCLC) cells with PARD6A and ECT2 and
CC       regulate ECT2 oncogenic activity by phosphorylation, which in turn
CC       promotes transformed growth and invasion. In response to nerve growth
CC       factor (NGF), acts downstream of SRC to phosphorylate and activate
CC       IRAK1, allowing the subsequent activation of NF-kappa-B and neuronal
CC       cell survival. Functions in the organization of the apical domain in
CC       epithelial cells by phosphorylating EZR. This step is crucial for
CC       activation and normal distribution of EZR at the early stages of
CC       intestinal epithelial cell differentiation. Forms a protein complex
CC       with LLGL1 and PARD6B independently of PARD3 to regulate epithelial
CC       cell polarity. Plays a role in microtubule dynamics in the early
CC       secretory pathway through interaction with RAB2A and GAPDH and
CC       recruitment to vesicular tubular clusters (VTCs). In human coronary
CC       artery endothelial cells (HCAEC), is activated by saturated fatty acids
CC       and mediates lipid-induced apoptosis. Involved in early synaptic long
CC       term potentiation phase in CA1 hippocampal cells and short term memory
CC       formation (By similarity). {ECO:0000250|UniProtKB:F1M7Y5,
CC       ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:10467349,
CC       ECO:0000269|PubMed:10906326, ECO:0000269|PubMed:11042363,
CC       ECO:0000269|PubMed:11724794, ECO:0000269|PubMed:12871960,
CC       ECO:0000269|PubMed:14684752, ECO:0000269|PubMed:15994303,
CC       ECO:0000269|PubMed:18270268, ECO:0000269|PubMed:19327373,
CC       ECO:0000269|PubMed:21189248, ECO:0000269|PubMed:21419810,
CC       ECO:0000269|PubMed:8226978, ECO:0000269|PubMed:9346882}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.13;
CC   -!- ACTIVITY REGULATION: Atypical PKCs (PRKCI and PRKCZ) exhibit an
CC       elevated basal enzymatic activity (that may be due to the interaction
CC       with SMG1 or SQSTM1) and are not regulated by diacylglycerol,
CC       phosphatidylserine, phorbol esters or calcium ions. Two specific sites,
CC       Thr-412 (activation loop of the kinase domain) and Thr-564 (turn
CC       motif), need to be phosphorylated for its full activation (By
CC       similarity). Might also be a target for novel lipid activators that are
CC       elevated during nutrient-stimulated insulin secretion. {ECO:0000250,
CC       ECO:0000269|PubMed:8524286}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=13.5 uM for ATP (for recombinant purified PRKCI)
CC         {ECO:0000269|PubMed:10906326};
CC         Vmax=7.4 pmol/min/mg enzyme {ECO:0000269|PubMed:10906326};
CC   -!- SUBUNIT: Forms a complex with SQSTM1 and MP2K5 (By similarity).
CC       Interacts directly with SQSTM1 (Probable). Interacts with IKBKB.
CC       Interacts with PARD6A, PARD6B and PARD6G. Part of a quaternary complex
CC       containing aPKC, PARD3, a PARD6 protein (PARD6A, PARD6B or PARD6G) and
CC       a GTPase protein (CDC42 or RAC1). Part of a complex with LLGL1 and
CC       PARD6B. Interacts with ADAP1/CENTA1. Interaction with SMG1, through the
CC       ZN-finger domain, activates the kinase activity. Interacts with CDK7.
CC       Forms a complex with RAB2A and GAPDH involved in recruitment onto the
CC       membrane of vesicular tubular clusters (VTCs). Interacts with ECT2
CC       ('Thr-359' phosphorylated form). Interacts with VAMP2
CC       (PubMed:17313651). Interacts with WDFY2 (via WD repeats 1-3)
CC       (PubMed:16792529). {ECO:0000250|UniProtKB:Q62074,
CC       ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:11257119,
CC       ECO:0000269|PubMed:11260256, ECO:0000269|PubMed:11724794,
CC       ECO:0000269|PubMed:11891849, ECO:0000269|PubMed:12725730,
CC       ECO:0000269|PubMed:12893243, ECO:0000269|PubMed:14570876,
CC       ECO:0000269|PubMed:15143057, ECO:0000269|PubMed:15590654,
CC       ECO:0000269|PubMed:15695176, ECO:0000269|PubMed:16452474,
CC       ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17313651,
CC       ECO:0000269|PubMed:19617897, ECO:0000269|PubMed:8524286,
CC       ECO:0000269|PubMed:9566925, ECO:0000305}.
CC   -!- INTERACTION:
CC       P41743; P60953: CDC42; NbExp=5; IntAct=EBI-286199, EBI-81752;
CC       P41743; P78545: ELF3; NbExp=2; IntAct=EBI-286199, EBI-1057285;
CC       P41743; P08151-1: GLI1; NbExp=3; IntAct=EBI-286199, EBI-16038799;
CC       P41743; Q96L34: MARK4; NbExp=2; IntAct=EBI-286199, EBI-302319;
CC       P41743; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-286199, EBI-16439278;
CC       P41743; Q96RE7: NACC1; NbExp=3; IntAct=EBI-286199, EBI-7950997;
CC       P41743; Q8TEW0: PARD3; NbExp=5; IntAct=EBI-286199, EBI-81968;
CC       P41743; Q9NPB6: PARD6A; NbExp=17; IntAct=EBI-286199, EBI-81876;
CC       P41743; Q9NPB6-2: PARD6A; NbExp=3; IntAct=EBI-286199, EBI-10693102;
CC       P41743; Q9BYG5: PARD6B; NbExp=22; IntAct=EBI-286199, EBI-295391;
CC       P41743; Q9BYG4: PARD6G; NbExp=7; IntAct=EBI-286199, EBI-295417;
CC       P41743; Q8ND90: PNMA1; NbExp=2; IntAct=EBI-286199, EBI-302345;
CC       P41743; Q05513: PRKCZ; NbExp=8; IntAct=EBI-286199, EBI-295351;
CC       P41743; P63000: RAC1; NbExp=3; IntAct=EBI-286199, EBI-413628;
CC       P41743; P48431: SOX2; NbExp=2; IntAct=EBI-286199, EBI-6124081;
CC       P41743; Q13501: SQSTM1; NbExp=10; IntAct=EBI-286199, EBI-307104;
CC       P41743; Q04917: YWHAH; NbExp=3; IntAct=EBI-286199, EBI-306940;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11891849,
CC       ECO:0000269|PubMed:15695176, ECO:0000269|PubMed:9566925}. Membrane
CC       {ECO:0000269|PubMed:16452474}. Endosome {ECO:0000269|PubMed:9566925}.
CC       Nucleus {ECO:0000269|PubMed:11891849, ECO:0000269|PubMed:15695176}.
CC       Note=Transported into the endosome through interaction with SQSTM1/p62.
CC       After phosphorylation by SRC, transported into the nucleus through
CC       interaction with KPNB1. Colocalizes with CDK7 in the cytoplasm and
CC       nucleus. Transported to vesicular tubular clusters (VTCs) through
CC       interaction with RAB2A. {ECO:0000269|PubMed:15695176,
CC       ECO:0000269|PubMed:9566925}.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in lung and brain, but also
CC       expressed at lower levels in many tissues including pancreatic islets.
CC       Highly expressed in non-small cell lung cancers.
CC       {ECO:0000269|PubMed:15994303, ECO:0000269|PubMed:7607695,
CC       ECO:0000269|PubMed:8226978}.
CC   -!- DOMAIN: The PB1 domain mediates interaction with SQSTM1. {ECO:0000250}.
CC   -!- DOMAIN: The C1 zinc finger does not bind diacylglycerol (DAG).
CC   -!- DOMAIN: The pseudosubstrate motif resembles the sequence around sites
CC       phosphorylated on target proteins, except the presence of a non-
CC       phosphorylatable residue in place of Ser, it modulates activity by
CC       competing with substrates. {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Thr-412 in the activation loop is not mandatory
CC       for activation (By similarity). Upon neuronal growth factor (NGF)
CC       stimulation, phosphorylated by SRC at Tyr-265, Tyr-280 and Tyr-334
CC       (PubMed:11713277, PubMed:16452474). Phosphorylation at Tyr-265
CC       facilitates binding to KPNB1/importin-beta regulating entry of PRKCI
CC       into the nucleus (PubMed:11891849). Phosphorylation on Tyr-334 is
CC       important for NF-kappa-B stimulation (PubMed:11713277). Phosphorylated
CC       at Thr-564 during the initial phase of long term potentiation (By
CC       similarity). {ECO:0000250|UniProtKB:F1M7Y5,
CC       ECO:0000250|UniProtKB:Q62074, ECO:0000269|PubMed:11713277,
CC       ECO:0000269|PubMed:11891849, ECO:0000269|PubMed:16452474}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA60171.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAB17011.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAH22016.3; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PRKCIID41857ch3q26.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L18964; AAA60171.1; ALT_INIT; mRNA.
DR   EMBL; L33881; AAB17011.1; ALT_INIT; mRNA.
DR   EMBL; CH471052; EAW78513.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78515.1; -; Genomic_DNA.
DR   EMBL; BC022016; AAH22016.3; ALT_INIT; mRNA.
DR   CCDS; CCDS3212.2; -.
DR   PIR; A49509; A49509.
DR   RefSeq; NP_002731.4; NM_002740.5.
DR   PDB; 1VD2; NMR; -; A=25-108.
DR   PDB; 1WMH; X-ray; 1.50 A; A=25-108.
DR   PDB; 1ZRZ; X-ray; 3.00 A; A=233-596.
DR   PDB; 3A8W; X-ray; 2.10 A; A/B=249-588.
DR   PDB; 3A8X; X-ray; 2.00 A; A/B=249-588.
DR   PDB; 3ZH8; X-ray; 2.74 A; A/B/C=248-594.
DR   PDB; 5LI1; X-ray; 2.00 A; A=248-596.
DR   PDB; 5LI9; X-ray; 1.79 A; A=248-596.
DR   PDB; 5LIH; X-ray; 3.25 A; A/B=248-596.
DR   PDB; 6ILZ; X-ray; 3.26 A; A/C/E/G=249-588.
DR   PDBsum; 1VD2; -.
DR   PDBsum; 1WMH; -.
DR   PDBsum; 1ZRZ; -.
DR   PDBsum; 3A8W; -.
DR   PDBsum; 3A8X; -.
DR   PDBsum; 3ZH8; -.
DR   PDBsum; 5LI1; -.
DR   PDBsum; 5LI9; -.
DR   PDBsum; 5LIH; -.
DR   PDBsum; 6ILZ; -.
DR   AlphaFoldDB; P41743; -.
DR   BMRB; P41743; -.
DR   SMR; P41743; -.
DR   BioGRID; 111570; 252.
DR   ComplexPortal; CPX-6183; PAR cell polarity complex, PARD6A-PRKCI variant.
DR   ComplexPortal; CPX-6193; PAR cell polarity complex, PARD6B-PRKCI variant.
DR   ComplexPortal; CPX-6194; PAR cell polarity complex, PARD6G-PRKCI variant.
DR   CORUM; P41743; -.
DR   DIP; DIP-31311N; -.
DR   ELM; P41743; -.
DR   IntAct; P41743; 153.
DR   MINT; P41743; -.
DR   STRING; 9606.ENSP00000295797; -.
DR   BindingDB; P41743; -.
DR   ChEMBL; CHEMBL2598; -.
DR   DrugBank; DB09096; Benzoyl peroxide.
DR   DrugBank; DB03777; Bisindolylmaleimide I.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugCentral; P41743; -.
DR   GuidetoPHARMACOLOGY; 1490; -.
DR   iPTMnet; P41743; -.
DR   PhosphoSitePlus; P41743; -.
DR   BioMuta; PRKCI; -.
DR   DMDM; 239938658; -.
DR   EPD; P41743; -.
DR   jPOST; P41743; -.
DR   MassIVE; P41743; -.
DR   MaxQB; P41743; -.
DR   PaxDb; P41743; -.
DR   PeptideAtlas; P41743; -.
DR   PRIDE; P41743; -.
DR   ProteomicsDB; 55477; -.
DR   Antibodypedia; 4271; 233 antibodies from 36 providers.
DR   DNASU; 5584; -.
DR   Ensembl; ENST00000295797.5; ENSP00000295797.4; ENSG00000163558.13.
DR   GeneID; 5584; -.
DR   KEGG; hsa:5584; -.
DR   MANE-Select; ENST00000295797.5; ENSP00000295797.4; NM_002740.6; NP_002731.4.
DR   UCSC; uc003fgs.3; human.
DR   CTD; 5584; -.
DR   DisGeNET; 5584; -.
DR   GeneCards; PRKCI; -.
DR   HGNC; HGNC:9404; PRKCI.
DR   HPA; ENSG00000163558; Low tissue specificity.
DR   MIM; 600539; gene.
DR   neXtProt; NX_P41743; -.
DR   OpenTargets; ENSG00000163558; -.
DR   PharmGKB; PA33768; -.
DR   VEuPathDB; HostDB:ENSG00000163558; -.
DR   eggNOG; KOG0695; Eukaryota.
DR   GeneTree; ENSGT00940000153497; -.
DR   HOGENOM; CLU_000288_63_29_1; -.
DR   InParanoid; P41743; -.
DR   OMA; RIQCFIC; -.
DR   OrthoDB; 614710at2759; -.
DR   PhylomeDB; P41743; -.
DR   TreeFam; TF102004; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   PathwayCommons; P41743; -.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-209543; p75NTR recruits signalling complexes.
DR   Reactome; R-HSA-420029; Tight junction interactions.
DR   SABIO-RK; P41743; -.
DR   SignaLink; P41743; -.
DR   SIGNOR; P41743; -.
DR   BioGRID-ORCS; 5584; 32 hits in 1116 CRISPR screens.
DR   ChiTaRS; PRKCI; human.
DR   EvolutionaryTrace; P41743; -.
DR   GeneWiki; PRKCI; -.
DR   GenomeRNAi; 5584; -.
DR   Pharos; P41743; Tchem.
DR   PRO; PR:P41743; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P41743; protein.
DR   Bgee; ENSG00000163558; Expressed in buccal mucosa cell and 204 other tissues.
DR   Genevisible; P41743; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl.
DR   GO; GO:0031252; C:cell leading edge; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0000139; C:Golgi membrane; IEA:GOC.
DR   GO; GO:0045171; C:intercellular bridge; IDA:HPA.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0120157; C:PAR polarity complex; IPI:ComplexPortal.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; IEA:Ensembl.
DR   GO; GO:0070160; C:tight junction; IC:ComplexPortal.
DR   GO; GO:0005524; F:ATP binding; TAS:UniProtKB.
DR   GO; GO:0004698; F:calcium-dependent protein kinase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005543; F:phospholipid binding; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004697; F:protein kinase C activity; ISS:BHF-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007015; P:actin filament organization; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; IEA:Ensembl.
DR   GO; GO:0045216; P:cell-cell junction organization; IMP:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:BHF-UCL.
DR   GO; GO:0007010; P:cytoskeleton organization; NAS:UniProtKB.
DR   GO; GO:0035089; P:establishment of apical/basal cell polarity; IEA:Ensembl.
DR   GO; GO:0045197; P:establishment or maintenance of epithelial cell apical/basal polarity; IDA:ComplexPortal.
DR   GO; GO:0042462; P:eye photoreceptor cell development; IEA:Ensembl.
DR   GO; GO:0048194; P:Golgi vesicle budding; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0061024; P:membrane organization; NAS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:WormBase.
DR   GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0060252; P:positive regulation of glial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0046326; P:positive regulation of glucose import; ISS:BHF-UCL.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; TAS:Reactome.
DR   GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006612; P:protein targeting to membrane; NAS:UniProtKB.
DR   GO; GO:0099072; P:regulation of postsynaptic membrane neurotransmitter receptor levels; IEA:Ensembl.
DR   GO; GO:0070555; P:response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0046903; P:secretion; NAS:UniProtKB.
DR   GO; GO:0016192; P:vesicle-mediated transport; TAS:UniProtKB.
DR   CDD; cd00029; C1; 1.
DR   CDD; cd06404; PB1_aPKC; 1.
DR   CDD; cd05618; STKc_aPKC_iota; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR034661; aPKC_iota.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR034877; PB1_aPKC.
DR   InterPro; IPR000270; PB1_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR012233; PKC.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF00564; PB1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000554; PKC_zeta; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00666; PB1; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57889; SSF57889; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS51745; PB1; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cytoplasm; Endosome; Kinase;
KW   Membrane; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Proto-oncogene; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Tumor suppressor; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   CHAIN           2..596
FT                   /note="Protein kinase C iota type"
FT                   /id="PRO_0000055710"
FT   DOMAIN          25..108
FT                   /note="PB1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01081"
FT   DOMAIN          254..522
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          523..594
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   ZN_FING         140..190
FT                   /note="Phorbol-ester/DAG-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          1..23
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2..253
FT                   /note="Regulatory domain"
FT   REGION          2..28
FT                   /note="Required for interaction with RAB2"
FT   REGION          72..91
FT                   /note="Interaction with PARD6A"
FT   REGION          220..246
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           125..134
FT                   /note="Pseudosubstrate"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        1..18
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        378
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         260..268
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         283
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylproline"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         3
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         7
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         8
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         9
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         265
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000269|PubMed:11713277,
FT                   ECO:0000269|PubMed:11891849"
FT   MOD_RES         280
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000269|PubMed:11713277"
FT   MOD_RES         334
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000269|PubMed:11713277"
FT   MOD_RES         412
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000305|PubMed:16125198"
FT   MOD_RES         564
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:16125198,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
FT   VARIANT         118
FT                   /note="P -> L (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042322"
FT   VARIANT         130
FT                   /note="R -> C (in dbSNP:rs56154494)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042323"
FT   MUTAGEN         29
FT                   /note="K->A: No effect on interaction with SQSTM1."
FT                   /evidence="ECO:0000269|PubMed:15143057"
FT   MUTAGEN         72
FT                   /note="D->A: Loss of interaction with ECT2, PARD6A and with
FT                   SQSTM1."
FT                   /evidence="ECO:0000269|PubMed:15143057,
FT                   ECO:0000269|PubMed:15590654, ECO:0000269|PubMed:19617897"
FT   MUTAGEN         85
FT                   /note="E->A: Slight decrease of interaction with PARD6A.
FT                   Loss of interaction with PARD6A; when associated with
FT                   A-91."
FT                   /evidence="ECO:0000269|PubMed:15590654"
FT   MUTAGEN         91
FT                   /note="R->A: Slight decrease of interaction with PARD6A.
FT                   Loss of interaction with PARD6A; when associated with
FT                   A-85."
FT                   /evidence="ECO:0000269|PubMed:15590654"
FT   MUTAGEN         265
FT                   /note="Y->F: No effect on the SRC-mediated phosphorylation
FT                   state. No effect on SRC-induced enzyme activity. Little
FT                   effect on TRAF6-mediated activation of NF-kappa-B.
FT                   Decreased binding to KPNB1/importin-beta."
FT                   /evidence="ECO:0000269|PubMed:11713277,
FT                   ECO:0000269|PubMed:11891849"
FT   MUTAGEN         274
FT                   /note="K->R: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:10906326"
FT   MUTAGEN         274
FT                   /note="K->W: Abolishes activity."
FT                   /evidence="ECO:0000269|PubMed:10906326"
FT   MUTAGEN         280
FT                   /note="Y->F: No effect on the SRC-mediated phosphorylation
FT                   state. No effect on SRC-induced enzyme activity. No effect
FT                   on TRAF6-mediated activation of NF-kappa-B."
FT                   /evidence="ECO:0000269|PubMed:11713277"
FT   MUTAGEN         334
FT                   /note="Y->F: No effect on the SRC-mediated phosphorylation
FT                   state. Significant reduction of SRC-induced enzyme
FT                   activity. Greatly reduced TRAF6-mediated activation of
FT                   NF-kappa-B. Reduces NGF-dependent cell survival."
FT                   /evidence="ECO:0000269|PubMed:11713277"
FT   CONFLICT        485
FT                   /note="L -> M (in Ref. 4; AAH22016)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        508
FT                   /note="H -> L (in Ref. 4; AAH22016)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        560
FT                   /note="P -> R (in Ref. 4; AAH22016)"
FT                   /evidence="ECO:0000305"
FT   STRAND          26..32
FT                   /evidence="ECO:0007829|PDB:1WMH"
FT   STRAND          35..41
FT                   /evidence="ECO:0007829|PDB:1WMH"
FT   HELIX           47..57
FT                   /evidence="ECO:0007829|PDB:1WMH"
FT   STRAND          67..71
FT                   /evidence="ECO:0007829|PDB:1WMH"
FT   STRAND          73..75
FT                   /evidence="ECO:0007829|PDB:1VD2"
FT   STRAND          77..79
FT                   /evidence="ECO:0007829|PDB:1WMH"
FT   HELIX           83..95
FT                   /evidence="ECO:0007829|PDB:1WMH"
FT   STRAND          101..106
FT                   /evidence="ECO:0007829|PDB:1WMH"
FT   HELIX           251..253
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   STRAND          254..262
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   STRAND          264..273
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   TURN            274..277
FT                   /evidence="ECO:0007829|PDB:3A8X"
FT   STRAND          279..286
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           287..289
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           293..309
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   STRAND          310..315
FT                   /evidence="ECO:0007829|PDB:6ILZ"
FT   STRAND          318..323
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   STRAND          325..332
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   STRAND          337..339
FT                   /evidence="ECO:0007829|PDB:6ILZ"
FT   HELIX           340..347
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           352..371
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           381..383
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   STRAND          384..386
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   STRAND          388..390
FT                   /evidence="ECO:0007829|PDB:3ZH8"
FT   STRAND          392..394
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           397..399
FT                   /evidence="ECO:0007829|PDB:3A8X"
FT   HELIX           417..419
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           422..425
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           433..448
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   TURN            452..457
FT                   /evidence="ECO:0007829|PDB:3A8X"
FT   HELIX           467..476
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           487..496
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   TURN            501..503
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   TURN            505..507
FT                   /evidence="ECO:0007829|PDB:1ZRZ"
FT   TURN            509..511
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           512..517
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           520..522
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           527..531
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   TURN            545..547
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           549..551
FT                   /evidence="ECO:0007829|PDB:3A8X"
FT   HELIX           554..557
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           568..571
FT                   /evidence="ECO:0007829|PDB:5LI9"
FT   HELIX           576..579
FT                   /evidence="ECO:0007829|PDB:5LI9"
SQ   SEQUENCE   596 AA;  68262 MW;  1E3F8C1D4BFC734F CRC64;
     MPTQRDSSTM SHTVAGGGSG DHSHQVRVKA YYRGDIMITH FEPSISFEGL CNEVRDMCSF
     DNEQLFTMKW IDEEGDPCTV SSQLELEEAF RLYELNKDSE LLIHVFPCVP ERPGMPCPGE
     DKSIYRRGAR RWRKLYCANG HTFQAKRFNR RAHCAICTDR IWGLGRQGYK CINCKLLVHK
     KCHKLVTIEC GRHSLPQEPV MPMDQSSMHS DHAQTVIPYN PSSHESLDQV GEEKEAMNTR
     ESGKASSSLG LQDFDLLRVI GRGSYAKVLL VRLKKTDRIY AMKVVKKELV NDDEDIDWVQ
     TEKHVFEQAS NHPFLVGLHS CFQTESRLFF VIEYVNGGDL MFHMQRQRKL PEEHARFYSA
     EISLALNYLH ERGIIYRDLK LDNVLLDSEG HIKLTDYGMC KEGLRPGDTT STFCGTPNYI
     APEILRGEDY GFSVDWWALG VLMFEMMAGR SPFDIVGSSD NPDQNTEDYL FQVILEKQIR
     IPRSLSVKAA SVLKSFLNKD PKERLGCHPQ TGFADIQGHP FFRNVDWDMM EQKQVVPPFK
     PNISGEFGLD NFDSQFTNEP VQLTPDDDDI VRKIDQSEFE GFEYINPLLM SAEECV
//
